<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304757</url>
  </required_header>
  <id_info>
    <org_study_id>SanghaiXinhua</org_study_id>
    <nct_id>NCT02304757</nct_id>
  </id_info>
  <brief_title>99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Decreased Bone Mineral Density</brief_title>
  <official_title>Randomized Trial of 99Tc-MDP and Alendronate Sodium in Postmenopausal Women With Differentiated Thyroid Cancer and Decrease in Bone Mineral Density Treated With Supraphysiological Doses of Thyroid Hormone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of
      levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of
      osteoporosis. Therefore, the investigators try to investigate the effects of 99Tc-MDP,
      calcium containing vitamin D alone and fosamax (alendronate sodium) in postmenopausal women
      with DTC and decreased bone mineral density (BMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of
      levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of
      osteoporosis. Therefore, the investigators try to investigate the effects of Technetium
      [99Tc] Methylenediphosphonate (99Tc-MDP), calcium containing vitamin D alone and fosamax
      (alendronate sodium) in postmenopausal women with DTC and decreased bone mineral density
      (BMD). The investigators therefore randomize 58 patients with slightly decreased BMD (T or
      Z-score in lumbar spine or neck region of femur &gt; -2.0 SD by dual energy X-ray) taking
      suppressive doses of L-T4 to treatment with 99Tc-MDP (low dose) 10mg Intravenous drip every
      1week for ten weeks, every 2 weeks for 22 weeks, every 1 month for 4 months, or calcium
      containing vitamin D alone. The control group, namely, 600mg calcium group containing vitamin
      D everyday. The investigators also randomize 148 patients with obviously decreased BMD (T or
      Z-score in lumbar spine or neck region of femur≤-2.0 SD) taking suppressive doses of L-T4 to
      treatment with 99Tc-MDP (high dose)15mg ivdripIntravenous drip every 1week for ten weeks,
      every 2 weeks for 22 weeks, every 1 month for 4 months (99Tc-MDP), or fosamax 70mg po for 12
      months. BMD of the spine and hip will be measured by dual energy x-ray absorptiometry bone
      densitometer. The spine was measured in the posterior projection, and results are reported
      for the total spine lumbar 1-4. The hip was measured in the standard projection, and results
      are reported for femoral neck, trochanter, and total hip; the femoral neck was chosen to
      represent a site rich in cortical bone, and the trochanter to represent a site relatively
      rich in trabecular bone. Patients have measurements of serum alkaline phosphatase, bone
      turnover markers, osteocalcin, C-telopeptides of type I collagen (CTX), Type I N-procollagen
      terminal propeptide,etc every 3, months for 1 yr. We also evaluate the bone pain by numerical
      rating scale (NRS), the quality of life by Short Form-36 (SF-36) scores.

      All assays were performed by a technician who was blinded regarding the subjects' treatment
      assignment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density in lumbar and hip</measure>
    <time_frame>0, and 3, 6, 12 months after treatment.</time_frame>
    <description>The changes of T score in lumbar and hip by dual energy x-ray absorptiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone turnover markers</measure>
    <time_frame>0, and 3, 6, 12 months after treatment.</time_frame>
    <description>bone turnover markers including osteocalcin, C-telopeptides of type I collagen (CTX), Type I N-procollagen terminal propeptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone pain by numerical rating scale</measure>
    <time_frame>0, and 3, 6, 12 months after treatment.</time_frame>
    <description>On numerical rating scale of 0 to 10 where 0 is no pain and 10 is the worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>0, and 3, 6, 12 months after treatment.</time_frame>
    <description>health-related quality of life questionnaire by Short Form-36 (SF-36) scores including physical health (physical functioning; physical role; bodily pain; general health) ;Mental health (vitality; social functioning; emotional role; mental health).Minimum score 0,maximum score, scores above 50 are better than the general population average for all scales, while scores below 50 are worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>3, 6 and 12 months after treatment.</time_frame>
    <description>A transient rash and phlebitis, gastrointestinal reaction.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Differentiated Thyroid Cancer</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>low dose 99Tc-MDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with slightly decreased BMD (T or Z-score in lumbar spine or neck region of femur &gt; -2.0 SD by dual energy X-ray) taking suppressive doses of L-T4 to treatment divided into 2 groups of 99Tc-MDP (Technetium [99Tc] methylenediphosphonate) and calcium alone.99Tc-MDP group:10mg Intravenous drip every 1week for ten weeks, every 2weeks for 22 weeks, every 1 month for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caltrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600mg caltrate containing vitamin D everyday for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose 99Tc-MDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>148 patients with obviously decreased BMD (T or Z-score in lumbar spine or neck region of femur≤-2.0 SD) taking suppressive doses of L-T4 divided into 2 groups of 99Tc-MDP and or fosamax. 99Tc-MDP group:15mg 99Tc-MDP Intravenous drip every 1week for ten weeks, every 2weeks for 22 weeks, every 1 month for 4 months (99Tc-MDP) for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fosamax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70mg po every week for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99Tc-MDP</intervention_name>
    <description>99Tc-MDP, H20000218</description>
    <arm_group_label>low dose 99Tc-MDP</arm_group_label>
    <arm_group_label>high dose 99Tc-MDP</arm_group_label>
    <other_name>Yunke,Technetium [99Tc] Methylenediphosphonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosamax</intervention_name>
    <description>H20080172</description>
    <arm_group_label>fosamax</arm_group_label>
    <other_name>alendronate sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caltrate</intervention_name>
    <description>Calcium 600 mg and vitamine D3 125iu.</description>
    <arm_group_label>low dose 99Tc-MDP</arm_group_label>
    <arm_group_label>Caltrate</arm_group_label>
    <arm_group_label>high dose 99Tc-MDP</arm_group_label>
    <arm_group_label>fosamax</arm_group_label>
    <other_name>Calcium Carbonate and Vitamin D3 tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Postmenopausal participants;

          2. Histologically established differentiated thyroid cancer (DTC) ;

          3. Total or near total thyroidectomy and radioiodine-131 thyroid residual ablation;

          4. Suppressive doses of levothyroxine (L-T4) with thyroid stimulating hormone( )≦the
             lower limit of the normal reference value;

          5. Participants voluntarily participate In the trial, and signed the informed consent.

        Exclusion Criteria:

          1. Secondary osteoporosis;

          2. Osteoporosis receiving treatment;

          3. Severe liver and kidney disease, bone marrow suppression;

          4. Esophageal reflux gastritis;

          5. Long term oral immunosuppressant, estrogen, selective estrogen receptor modulators.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chao Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui Wang, MD</last_name>
    <phone>86-02125078590</phone>
    <email>wanghauishanghai@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chao Ma, MD</last_name>
    <phone>86-02125078593</phone>
    <email>mc_7419@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nuclear Medicine Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Ma, MD</last_name>
      <phone>+86021-25078593</phone>
      <email>mc_7419@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hui Wang, MD</last_name>
      <phone>+86021-25078593</phone>
      <email>wanghuishanghai@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yanlei Huo, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suyun Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danyang Wang, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>McGriff NJ, Csako G, Gourgiotis L, Lori C G, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34(7-8):554-64.</citation>
    <PMID>12553495</PMID>
  </results_reference>
  <results_reference>
    <citation>Quan ML, Pasieka JL, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol. 2002 Jan;79(1):62-9; discussion 69-70. Review.</citation>
    <PMID>11754378</PMID>
  </results_reference>
  <results_reference>
    <citation>Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 2006 Jun;16(6):583-91.</citation>
    <PMID>16839260</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K, Greenspan SL. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab. 1998 Jul;83(7):2324-30.</citation>
    <PMID>9661603</PMID>
  </results_reference>
  <results_reference>
    <citation>Gong W, Dou H, Liu X, Sun L, Hou Y. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis. Clin Exp Pharmacol Physiol. 2012 Oct;39(10):886-93. doi: 10.1111/j.1440-1681.2012.12006.x.</citation>
    <PMID>23013134</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chao Ma</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>differentiated thyroid cancer</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>thyroid stimulating hormone suppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Methylene diphosphonate</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

